United Therapeutics Co. (NASDAQ:UTHR) Shares Bought by Park Avenue Securities LLC

Park Avenue Securities LLC grew its stake in United Therapeutics Co. (NASDAQ:UTHR) by 11.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,562 shares of the biotechnology company’s stock after buying an additional 155 shares during the quarter. Park Avenue Securities LLC’s holdings in United Therapeutics were worth $359,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the stock. Mariner LLC increased its holdings in shares of United Therapeutics by 8.9% during the 3rd quarter. Mariner LLC now owns 3,365 shares of the biotechnology company’s stock valued at $760,000 after purchasing an additional 275 shares in the last quarter. Natixis Advisors L.P. increased its holdings in United Therapeutics by 56.6% in the third quarter. Natixis Advisors L.P. now owns 21,319 shares of the biotechnology company’s stock valued at $4,815,000 after buying an additional 7,702 shares in the last quarter. O Shaughnessy Asset Management LLC raised its position in shares of United Therapeutics by 4.9% in the third quarter. O Shaughnessy Asset Management LLC now owns 2,300 shares of the biotechnology company’s stock worth $520,000 after acquiring an additional 107 shares during the period. Synovus Financial Corp purchased a new stake in shares of United Therapeutics during the 3rd quarter worth about $203,000. Finally, Caxton Associates LP acquired a new stake in shares of United Therapeutics during the 3rd quarter valued at about $213,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction dated Thursday, June 27th. The shares were sold at an average price of $316.62, for a total value of $1,139,832.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $41,160.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction that occurred on Thursday, June 27th. The stock was sold at an average price of $316.62, for a total value of $1,139,832.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $41,160.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 6,000 shares of the firm’s stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $232.37, for a total value of $1,394,220.00. Following the sale, the executive vice president now directly owns 36,710 shares of the company’s stock, valued at approximately $8,530,302.70. The disclosure for this sale can be found here. Insiders have sold a total of 126,344 shares of company stock worth $32,426,462 in the last quarter. Company insiders own 12.50% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on UTHR shares. HC Wainwright reaffirmed a “buy” rating and issued a $300.00 price target on shares of United Therapeutics in a report on Thursday, May 2nd. JPMorgan Chase & Co. increased their target price on United Therapeutics from $280.00 to $300.00 and gave the company an “overweight” rating in a research report on Tuesday, May 21st. The Goldman Sachs Group boosted their price target on shares of United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd. Oppenheimer increased their price objective on shares of United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a report on Thursday, May 2nd. Finally, Wells Fargo & Company boosted their target price on shares of United Therapeutics from $325.00 to $350.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 12th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $312.22.

United Therapeutics Stock Up 0.5 %

Shares of NASDAQ UTHR opened at $318.55 on Monday. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04. The company has a 50-day moving average of $274.77 and a 200 day moving average of $243.95. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $321.80. The stock has a market cap of $14.13 billion, a PE ratio of 15.06, a P/E/G ratio of 1.40 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, beating the consensus estimate of $5.63 by $0.54. The firm had revenue of $677.70 million during the quarter, compared to analysts’ expectations of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The business’s revenue for the quarter was up 33.7% on a year-over-year basis. During the same quarter last year, the firm earned $4.86 earnings per share. As a group, sell-side analysts predict that United Therapeutics Co. will post 24.73 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.